Detection of fumarate–glutathione adducts in the portal vein blood of rats: evidence for rapid dimethylfumarate metabolism

[1]  David H. Miller,et al.  Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. , 2012, The New England journal of medicine.

[2]  D. Arnold,et al.  Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. , 2012, The New England journal of medicine.

[3]  Martin Röcken,et al.  Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells , 2012 .

[4]  U. Mrowietz,et al.  Pharmacokinetics of anti-psoriatic fumaric acid esters in psoriasis patients , 2010, Archives of Dermatological Research.

[5]  T. Luger,et al.  Efficacy and safety of fumaric acid esters in the long‐term treatment of psoriasis – A retrospective study (FUTURE) , 2009, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[6]  Ludwig Kappos,et al.  Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study , 2008, The Lancet.

[7]  U. Mrowietz,et al.  Dimethylfumarate inhibits nuclear binding of nuclear factor κB but not of nuclear factor of activated T cells and CCAAT/enhancer binding protein β in activated human T cells , 2007, The British journal of dermatology.

[8]  K. Lemr,et al.  Evidence of covalent interaction of fumaric acid esters with sulfhydryl groups in peptides. , 2005, Journal of mass spectrometry : JMS.

[9]  P. Nibbering,et al.  Pharmacokinetics of oral fumarates in healthy subjects. , 2004, British journal of clinical pharmacology.

[10]  Felix Treumer,et al.  Dimethylfumarate is a potent inducer of apoptosis in human T cells. , 2003, The Journal of investigative dermatology.

[11]  S. Wolffram,et al.  Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters , 2003, Biopharmaceutics & drug disposition.

[12]  P. Altmeyer,et al.  Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use , 1999, The British journal of dermatology.

[13]  P. Altmeyer,et al.  Fumaric Acid Esters Suppress Peripheral CD4- and CD8-Positive Lymphocytes in Psoriasis , 1998, Dermatology.

[14]  K. Vasquez,et al.  Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[15]  U. Mrowietz,et al.  Detection of metabolites of fumaric acid esters in human urine: implications for their mode of action. , 2009, The Journal of investigative dermatology.

[16]  U. Mrowietz,et al.  Reactivity of dimethyl fumarate and methylhydrogen fumarate towards glutathione and N-acetyl-L-cysteine--preparation of S-substituted thiosuccinic acid esters. , 2007, Bioorganic & medicinal chemistry.